NCT02049593View on ClinicalTrials.gov

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 12, 2014

Primary Completion Date

October 7, 2019

Study Completion Date

October 7, 2019

Conditions
Metastatic CancerUnspecified Adult Solid Tumor
Interventions
DRUG

PARP inhibitor BMN-673

Given PO

DRUG

temozolomide

Given PO

DRUG

irinotecan hydrochloride

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90095

Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

collaborator

BioMarin Pharmaceutical

INDUSTRY

collaborator

Medivation, Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER